Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-21
    E.g., 2018-10-21

Archive Search

259517 items
12:00 AM, Apr 12, 1993  |  BioCentury | Finance

Revving up against FASB rule

Revving up against FASB rule Companies that don't like the decision handed down last week by the Financial Accounting Standards Board regarding the treatment of stock options will have three years to lobby against its implementation...
12:00 AM, Apr 05, 1993  |  BioCentury | Politics, Policy & Law

Agbio celebrates end of logjam

WASHINGTON - President Clinton's affinity for solutions that offer something-for-everybody has been criticized as a sign of weak leadership that pleases nobody, but the emergence of the administration's agricultural biotechnology policy may change all that....
12:00 AM, Apr 05, 1993  |  BioCentury | Politics, Policy & Law

Text of the Stark legislation

(1) IN GENERAL - IF - (A) there is a windfall profit on any orphan drug for any taxable year, and (B) any portion of such taxable year is within the exclusivity period for such drug, the...
12:00 AM, Apr 05, 1993  |  BioCentury | Finance

Who's responsible?

...
12:00 AM, Apr 05, 1993  |  BioCentury | Finance

Individual and collective

Individual and collective Sorting through the wreckage of the biotech financial markets is a useful exercise because it provides some insights into the nature of the industry and the kinds of attitudes that may be...
12:00 AM, Apr 05, 1993  |  BioCentury | Finance

First quarter chronicles

First quarter chroniclesHow the BioCentury 100 fared as industry and political events sent stocks reeling. Election weekNov. 6 close 1344.00, up 6% Centoxin trial suspended Jan. 18Jan. 22 close 1443.69, down 4% Disappointing AMGN earningsFeb. 5 close 1323.13,...
12:00 AM, Apr 05, 1993  |  BioCentury | Finance

Mapping the plunge

Mapping the plunge Political uncertainty over the course of health care loomed large in the first quarter and will continue to do so, but biotech industry insiders place the lion's share of the blame...
12:00 AM, Mar 29, 1993  |  BioCentury | Finance

Analyst picks & changes

Magainin Pharmaceuticals Inc. H&Q analyst Timothy Wilson initiated coverage of Magainin Pharmaceuticals Inc. with a "buy." Wilson said MAGN's magainin antimicrobial compounds have two key advantages over more conventional drugs: they are able to kill an...
12:00 AM, Mar 29, 1993  |  BC Week In Review | Company News  |  Deals

Enzon Inc. deal

Enzon Inc. (ENZN)   Enzon Inc. (ENZN) and American Veterinary Products Inc. have reached a joint development and licensing agreement to develop ENZN's blood substitute for use as a substitute for whole blood in cases of...
12:00 AM, Mar 29, 1993  |  BC Week In Review | Company News  |  Deals

Houghten deal

Houghten Pharmaceuticals Inc.   American Cyanamid's agricultural research division and Houghten Pharmaceuticals Inc. have signed a research collaboration agreement, under which Cyanamid will use its proprietary assays in the animal health and agricultural fields to...

Pages